Swiss National Bank Reduces Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Swiss National Bank decreased its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 115,400 shares of the specialty pharmaceutical company’s stock after selling 1,600 shares during the quarter. Swiss National Bank’s holdings in Jazz Pharmaceuticals were worth $14,212,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of JAZZ. CIBC Asset Management Inc bought a new position in Jazz Pharmaceuticals in the 3rd quarter valued at $209,000. Natixis Advisors LLC boosted its stake in shares of Jazz Pharmaceuticals by 7.6% during the third quarter. Natixis Advisors LLC now owns 22,834 shares of the specialty pharmaceutical company’s stock valued at $2,544,000 after purchasing an additional 1,603 shares during the period. Advisors Asset Management Inc. grew its holdings in shares of Jazz Pharmaceuticals by 3.9% in the third quarter. Advisors Asset Management Inc. now owns 9,624 shares of the specialty pharmaceutical company’s stock worth $1,072,000 after purchasing an additional 364 shares during the last quarter. Foundry Partners LLC lifted its holdings in Jazz Pharmaceuticals by 10.9% during the 3rd quarter. Foundry Partners LLC now owns 3,362 shares of the specialty pharmaceutical company’s stock valued at $375,000 after buying an additional 331 shares in the last quarter. Finally, Thompson Siegel & Walmsley LLC boosted its position in Jazz Pharmaceuticals by 8.3% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 781,215 shares of the specialty pharmaceutical company’s stock valued at $87,035,000 after buying an additional 59,685 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $142.07 on Thursday. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $148.06. The business’s fifty day simple moving average is $130.66 and its 200-day simple moving average is $121.32. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The company has a market cap of $8.63 billion, a PE ratio of 20.01, a PEG ratio of 1.04 and a beta of 0.44.

Insider Activity at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $122.31, for a total transaction of $183,465.00. Following the sale, the chief executive officer now owns 439,744 shares in the company, valued at approximately $53,785,088.64. The trade was a 0.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Neena M. Patil sold 3,800 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the transaction, the executive vice president now directly owns 33,318 shares of the company’s stock, valued at $4,826,778.66. The trade was a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,736 shares of company stock valued at $4,022,825 in the last ninety days. Corporate insiders own 4.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on JAZZ shares. Piper Sandler reaffirmed an “overweight” rating and set a $176.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Morgan Stanley reaffirmed an “overweight” rating and set a $183.00 target price (up from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. Barclays reissued an “overweight” rating and set a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. UBS Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $145.00 to $179.00 in a report on Friday, March 7th. Finally, Truist Financial upped their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. One analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $187.71.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.